Profiles

Keywords
Last Name
Institution

Jennifer Goldman

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7401759793.
    My NIH COMMONS name is JGOLDMAN1.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Goldman JG, Vernaleo BA, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, Galvin JE, Marras C, Edwards J, Fields J, Golden R, Karlawish J, Levin B, Shulman L, Smith G, Tangney C, Thomas CA, Tröster AI, Uc EY, Coyan N, Ellman C, Ellman M, Hoffman C, Hoffman S, Simmonds D. Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 2018; 4:19. PMID: 29951580.
      View in: PubMed
    2. Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B. Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. Mov Disord. 2018 Apr; 33(4):528-536. PMID: 29624752.
      View in: PubMed
    3. Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP. Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Mov Disord. 2018 Apr; 33(4):503-510. PMID: 29488270.
      View in: PubMed
    4. Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 Mar; 33(3):499-500. PMID: 29460975.
      View in: PubMed
    5. Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018 Mar; 35(2):182-187. PMID: 29315761.
      View in: PubMed
    6. Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 Feb; 33(2):282-288. PMID: 29205509.
      View in: PubMed
    7. Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 Feb; 33(2):208-218. PMID: 29168899.
      View in: PubMed
    8. Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ. Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. 2017 Jul; 32(7):1056-1065. PMID: 28605056.
      View in: PubMed
    9. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 04; 89(1):88-100. PMID: 28592453.
      View in: PubMed
    10. Bailey M, Goldman JG. Characterizing Cognitive Impairment in Parkinson's Disease. Semin Neurol. 2017 04; 37(2):167-175. PMID: 28511257.
      View in: PubMed
    11. Goldman JG, Bledsoe IO, Merkitch D, Dinh V, Bernard B, Stebbins GT. Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. Neurology. 2017 Mar 28; 88(13):1265-1272. PMID: 28235816.
      View in: PubMed
    12. Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016 Oct 01; 73(10):1217-1224. PMID: 27571329.
      View in: PubMed
    13. Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP. Arguing against the proposed definition changes of PD. Mov Disord. 2016 Nov; 31(11):1619-1622. PMID: 27492190.
      View in: PubMed
    14. Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF. a-synuclein genetic variability: A biomarker for dementia in Parkinson disease. Ann Neurol. 2016 Jun; 79(6):991-9. PMID: 27091628.
      View in: PubMed
    15. Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Rudolph A, Casaceli C, Andrews H, Gwinn K, Sutherland M, Kopil C, Vincent L, Frasier M. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32. PMID: 27113479; PMCID: PMC5021110.
      View in: PubMed, PubMed Central
    16. Diederich NJ, Goldman JG, Stebbins GT, Goetz CG. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22. PMID: 26650182.
      View in: PubMed
    17. Goldman JG, Aggarwal NT, Schroeder CD. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegener Dis Manag. 2015 Oct; 5(5):425-43. PMID: 26517759; PMCID: PMC4968199.
      View in: PubMed, PubMed Central
    18. Goldman JG. Writer's cramp. Toxicon. 2015 Dec 01; 107(Pt A):98-104. PMID: 26391286.
      View in: PubMed
    19. Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson's disease. Mov Disord. 2015 Sep 15; 30(11):1471-89. PMID: 26297863.
      View in: PubMed
    20. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):95-102. PMID: 26296077; PMCID: PMC4724255 [Available on 01/01/17].
      View in: PubMed, PubMed Central
    21. David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, Comella CL, Vaillancourt DE, Corcos DM. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63. PMID: 26148003; PMCID: PMC4609235 [Available on 10/01/16].
      View in: PubMed, PubMed Central
    22. Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP. Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord. 2015 Apr 15; 30(5):728-33. PMID: 25650144; PMCID: PMC4397146.
      View in: PubMed, PubMed Central
    23. Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6. PMID: 25449653; PMCID: PMC4357536.
      View in: PubMed, PubMed Central
    24. Goldman JG, Stebbins GT, Leung V, Tilley BC, Goetz CG. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9. PMID: 25150770; PMCID: PMC4252982.
      View in: PubMed, PubMed Central
    25. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol. 2014 Aug; 27(4):434-41. PMID: 24978368; PMCID: PMC4181670.
      View in: PubMed, PubMed Central
    26. Neely KA, Kurani AS, Shukla P, Planetta PJ, Wagle Shukla A, Goldman JG, Corcos DM, Okun MS, Vaillancourt DE. Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor. Cereb Cortex. 2015 Nov; 25(11):4191-202. PMID: 24962992; PMCID: PMC4816778 [Available on 11/01/16].
      View in: PubMed, PubMed Central
    27. Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7. PMID: 24821679.
      View in: PubMed
    28. Chu Y, Goldman JG, Kelly L, He Y, Waliczek T, Kordower JH. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14. PMID: 24825319.
      View in: PubMed
    29. Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord. 2014 Apr 15; 29(5):608-21. PMID: 24757110; PMCID: PMC4126402.
      View in: PubMed, PubMed Central
    30. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol. 2014 Mar; 16(3):281. PMID: 24464490; PMCID: PMC3994190.
      View in: PubMed, PubMed Central
    31. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59. PMID: 24480486; PMCID: PMC3983409.
      View in: PubMed, PubMed Central
    32. Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kieburtz K. Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. J Parkinsons Dis. 2014; 4(4):585-9. PMID: 24989876; PMCID: PMC4371591.
      View in: PubMed, PubMed Central
    33. Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I. Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis. 2014; 4(2):131-7. PMID: 24296865; PMCID: PMC4380013.
      View in: PubMed, PubMed Central
    34. Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9. PMID: 24123267; PMCID: PMC4164432.
      View in: PubMed, PubMed Central
    35. Goetz CG, Vaughan CL, Goldman JG, Stebbins GT. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7. PMID: 23843193.
      View in: PubMed
    36. Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11. PMID: 23735187; PMCID: PMC3729741.
      View in: PubMed, PubMed Central
    37. Goldman JG, Eichenseer SR, Berry-Kravis E, Zimnowodzki S, Gregory A, Hogarth P, Hayflick SJ. Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation. Mov Disord. 2013 Sep; 28(10):1462-3. PMID: 23494994.
      View in: PubMed
    38. Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG, Berry-Kravis E, Foulds NC, Hammans SR, Desguerre I, Rodriguez D, Wilson C, Diedrich A, Green S, Tran H, Reese L, Woltjer RL, Hayflick SJ. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology. 2013 Jan 15; 80(3):268-75. PMID: 23269600; PMCID: PMC3589182.
      View in: PubMed, PubMed Central
    39. Kapur SS, Goldman JG. Spinocerebellar ataxia types 2 and 10: more than a coincidental association?-Reply. Arch Neurol. 2012 Nov 01; 69(11):1524-5. PMID: 23753686.
      View in: PubMed
    40. Kapur SS, Goldman JG. Two in one: report of a patient with spinocerebellar ataxia types 2 and 10. Arch Neurol. 2012 Sep; 69(9):1200-3. PMID: 22964913.
      View in: PubMed
    41. Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36. PMID: 22778009; PMCID: PMC3412930.
      View in: PubMed, PubMed Central
    42. Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34. PMID: 22410753; PMCID: PMC3366041.
      View in: PubMed, PubMed Central
    43. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar; 27(3):349-56. PMID: 22275317; PMCID: PMC3641655.
      View in: PubMed, PubMed Central
    44. Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53. PMID: 22162144.
      View in: PubMed
    45. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15; 26(10):1814-24. PMID: 21661055; PMCID: PMC3181006.
      View in: PubMed, PubMed Central
    46. Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24. PMID: 21635198; PMCID: PMC3152685.
      View in: PubMed, PubMed Central
    47. Poon C, Robichaud JA, Corcos DM, Goldman JG, Vaillancourt DE. Combined measures of movement and force variability distinguish Parkinson's disease from essential tremor. Clin Neurophysiol. 2011 Nov; 122(11):2268-75. PMID: 21570904; PMCID: PMC3183282.
      View in: PubMed, PubMed Central
    48. Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2. PMID: 21506165; PMCID: PMC3142314.
      View in: PubMed, PubMed Central
    49. Goldman JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis. 2011 Mar 02; 2011:675630. PMID: 21403865; PMCID: PMC3049364.
      View in: PubMed, PubMed Central
    50. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord. 2010 Nov 15; 25(15):2501-7. PMID: 20878991; PMCID: PMC2978783.
      View in: PubMed, PubMed Central
    51. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50. PMID: 18823039.
      View in: PubMed
    52. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837. PMID: 17542011.
      View in: PubMed
    53. Goldman JG, Goetz CG. History of Parkinson's disease. Handb Clin Neurol. 2007; 83:107-28. PMID: 18808912.
      View in: PubMed
    54. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4. PMID: 15313848.
      View in: PubMed
    55. Goldman JG, Comella CL. Treatment of dystonia. Clin Neuropharmacol. 2003 Mar-Apr; 26(2):102-8. PMID: 12671530.
      View in: PubMed
    Goldman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (157) concept(s)
    _
    Co-Authors Expand Description
    See all (13) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department